Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:33:15 2024-07-12 pm EDT			5-day change	1st Jan Change
0.00075 ^USD	-10.71%		-20.00%	-93.33%

Jun. 25	Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	CI
Jun. 20	Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding	CI

Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022

November 14, 2022 at 04:34 pm EST

Propanc Biopharma, Inc. reported earnings results for the first quarter ended September 30, 2022. For the first quarter, the company reported net loss was USD 0.617295 million compared to USD 0.490658 million a year ago.

Latest news about Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	Jun. 25	CI
Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding	Jun. 19	CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	Jun. 16	CI
Propanc Biopharma, Inc. Enters into and Closed a Loan Agreement with an Investor	Jun. 13	CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	May. 30	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 15	CI
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	Apr. 16	CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	Apr. 15	CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	Feb. 29	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 20	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	Jan. 16	CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	Dec. 10	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	Dec. 03	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	23-10-28	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	23-10-19	CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	23-10-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	23-10-11	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	23-08-30	CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding	23-08-29	CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC	23-08-22	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding	23-08-15	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	23-08-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.12 million in funding	23-08-14	CI

Chart Propanc Biopharma, Inc.

Duration

Period

More charts

Company Profile

Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROPANC BIOPHARMA, INC.	-93.33%	137K
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs